Intensive science summer
Esbjörn Melin, researcher and doctoral student at the Epilepsy Centre, Lund University Faculty of Medicine, looks forward to a busy summer. Much of the research behind CombiGene’s CG01epilepsy project has been conducted at the Epilepsy Centre, Lund University Faculty of Medicine. This work includes the successful proof-of-concept study which Esbjörn presented at the13th European Congress on Epileptology in Vienna, Austria.
This summer, Esbjörn will particpate in two major international conferences. The first is the 33rd International Epilepsy Conference in Bangkok (22-26 June), where Esbjörn will give a poster presentation. The Bangkok conference, held every other year, is one of the most important conferences for global epilepsy research
The other conference is the 12th International NPY-PYY-PP Gairdner International Symposium (27-31 July) in Canada, to which Esbjörn has been invited to present the NPY/Y2 study, the science that is the very core of CombiGene’s candidate drug, CG01. Esbjörn will also give a poster presentation at this conference.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.